Vanguard Capital Management Reports New 5.21% Passive Stake in Halozyme Therapeutics Inc

Vanguard Capital Management LLC filed a Schedule 13G on April 30, 2026, reporting a new 5.21% passive ownership stake in Halozyme Therapeutics Inc (HALO). As of the event date on March 31, 2026, Vanguard beneficially owns 6,173,547 shares of common stock. The filing indicates that Vanguard holds sole dispositive power over all 6,173,547 shares, while maintaining sole voting power over 902,329 shares. This position was established in the ordinary course of business, with the filer certifying that the acquisition was not intended to influence or change the control of the issuer. The reported holdings include securities managed by various Vanguard affiliates, including Vanguard Asset Management Limited and Vanguard Global Advisers, LLC. This filing represents an increase from a previous 0% ownership level, crossing the 5% regulatory threshold for Halozyme Therapeutics.